Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share.
March 30, 2022
· 2 min read